File this under “Not a moment too soon.”
After years of back-and-forth deliberations, the U.S. Food and Drug Administration has agreed to review a rare disease drug developed by a small company that planned to shelve further work if the agency did not take this long-sought step.
Specifically, the FDA accepted a new drug application from Stealth BioTherapeutics for a treatment to combat Barth syndrome, which causes an enlarged heart, muscle weakness, and a shortened life expectancy. The agency also announced it would hold an advisory committee meeting to review the application, but no date has been set. However, the FDA did not issue a priority review, which could delay approval.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect